Endoplasmic reticulum stress in beta cells

EQS-News: Defence Therapeutics Inc.: DEFENCE’S LUNG CANCER GLP TOX STUDY ON ITS INTRANASAL ACCUTOXTM FORMULATION ADVANCES

Retrieved on: 
Thursday, February 2, 2023
Toxicity, Kinetics, MTD, Index (publishing), Lymphoma, Therapy, Lung cancer, Melanoma, Endoplasmic reticulum stress in beta cells, DNA, Dog, Safety, PK, Breast, Plasma, Human, Patient, Toxicology, Mouse, Research, Cancer, Clinical trial, GLP, USD, RATS, Pharmaceutical industry, Vaccine, Defense

Vancouver, BC, Canada, January 31st, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its GLP studies on a new intranasal AccuTOXTM formulation.

Key Points: 
  • Vancouver, BC, Canada, January 31st, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its GLP studies on a new intranasal AccuTOXTM formulation.
  • This milestone is crucial to initiate a Phase I trial for this drug in the context of lung cancer.
  • Building upon this success, Defence designed a new non-invasive formulation allowing the drug to be delivered intranasally to reach lung-established tumors.
  • Lung cancer is the deadliest cancer worldwide, accounting for 1.79 million deaths in 2020.

Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035

Retrieved on: 
Friday, September 2, 2022
Biotechnology, FDA, Pharmaceutical, Health, Amyotrophic lateral sclerosis, Prescription Drug User Fee Act, COVID-19, NDA, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, EMEA, Medication, PDUFA, Degenerative disease, Food, LinkedIn, SEC, U.S. Securities and Exchange Commission, Endoplasmic reticulum stress in beta cells, Nasdaq, FDA, Neurodegeneration, Company, Twitter, Private Securities Litigation Reform Act, Review, Trial of the century, ALS, Pharmaceutical industry

The second meeting of the PCNSDAC for the AMX0035 NDA is scheduled for 12:00 p.m.

Key Points: 
  • The second meeting of the PCNSDAC for the AMX0035 NDA is scheduled for 12:00 p.m.
  • The Company is not responsible for the content of, nor the statements made in, the briefing materials that were prepared by the FDA.
  • The PCNSDAC previously met on March 30, 2022 to discuss the NDA for AMX0035 for the treatment of ALS.
  • Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative community through the discovery and development of innovative new treatments.

DGAP-News: Defence Therapeutics Inc.:  BREAKTHROUGH DISCOVERY: DEFENCE’S ACCUMTM VARIANT 'A1' CONVERTS MESENCHYMAL STROMAL CELLS INTO POTENT ANTIGEN PRESENTING CELLS SUITABLE FOR CANCER VACCINATION

Retrieved on: 
Wednesday, August 17, 2022
Immunity, DC, ADC, ARM, Survival, APC, Unfolded protein response, GLP, Gene, Inflammation, CEO, Forward-looking statement, Catastrophic illness, A1, Technology, Cancer, Clinical trial, DGAP, B cell, Patient, Engineering, Therapy, Cell, Company, Infection, CTL, Vaccine, News, Control, Microsoft, CTLS, CSE, Melanoma, Endoplasmic reticulum stress in beta cells, Wild Arms, Animal, Antigen, Immune system, Security (finance), Pharmaceutical industry, BC, Defense

With respect to cancer, the immune system relies on dendritic cells (DCs), a subset of potent endogenous APCs, to prime cytotoxic T lymphocytes (CTLs).

Key Points: 
  • With respect to cancer, the immune system relies on dendritic cells (DCs), a subset of potent endogenous APCs, to prime cytotoxic T lymphocytes (CTLs).
  • Unfortunately, however, most cancer cells can acquire strategies to escape DC-elicited immunity resulting in the development of deadly tumors.
  • To overcome this issue, Defence Therapeutics applied a novel strategy, which consists at reprogramming the immune-suppressive MSCs to convert them into potent APCs.
  • This application discovered that it uses a unique cell type to which tumor cells are not programmed to respond.

EtiraRx's Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials

Retrieved on: 
Thursday, June 2, 2022
Endoplasmic reticulum stress in beta cells, Cell death, CEO, Glioblastoma, ER, Therapeutic index, Patient, DRS, Protein folding, LIPA, Heel, Endoplasmic reticulum, Achilles, Vaccine, Pharmaceutical industry, DALLAS, List of Nature Research journals

DALLAS, June 2, 2022 /PRNewswire/ -- A scientific team, led by the scientific founders of EtiraRx, has identified a small molecule, ERX-41, as a novel oral therapeutic agent that may have utility in treating multiple solid cancers, including triple negative breast cancer, glioblastoma, ovarian and pancreatic cancers. EtiraRx, headquartered in Biolabs Pegasus Park, plans to initiate clinical trials as early as the first quarter of 2023.

Key Points: 
  • EtiraRx, headquartered in Biolabs Pegasus Park, plans to initiate clinical trials as early as the first quarter of 2023.
  • Jung-Mo Ahn, Ganesh Raj and Ratna Vadlamudi, identified that ERX-41 dramatically enhances endoplasmic reticulum (ER) stress in cancer cells.
  • The study set the foundation for clinical trials with patients with therapy-resistant cancers that are vulnerable to enhanced ER stress.
  • Russell Hayward, CEO EtiraRx, said, "ERX-41 has the potential to be a first-in-class oral therapy that kills aggressive therapy-resistant cancers.

ProJenX launches to advance novel, targeted therapies for ALS and other brain diseases

Retrieved on: 
Wednesday, February 16, 2022
Columbia University, Chemistry, Amyotrophic lateral sclerosis, Pathology, Columbia, Patient, Family, MEC, Entrepreneurship, Center, Friends, Core, Endoplasmic reticulum stress in beta cells, MAP4, Precision medicine, Directorate of Research and Civil Affairs, Disease, Prosetín, Synthetic biology, ALS, Project ALS, Neurological disorder, Lipidomics, Artificial intelligence, Regenerative medicine, Global Medical Excellence Cluster, Therapy, Project, Multimedia, Drug discovery, Translation, Cell biology, Biology, Drug development, LLC, Heart, Pharmaceutical industry, Research, DRS

A $5.1M seed financing was led by Medical Excellence Capital, which created ProJenX in collaboration with Project ALS, a leading nonprofit organization committed to ALS research, and with renowned researchers at Columbia University.

Key Points: 
  • A $5.1M seed financing was led by Medical Excellence Capital, which created ProJenX in collaboration with Project ALS, a leading nonprofit organization committed to ALS research, and with renowned researchers at Columbia University.
  • ProJenX will build on the efforts initiated by Columbia and Project ALS to advance prosetin through ALS clinical trials with urgency, humanity, and scientific rigor.
  • The company is named in honor of Project ALS founder Jenifer Estess, whowas diagnosed with ALS at age 35.
  • ProJenX is a clinical stage biotechnology company with novel, brain-penetrant, targeted therapies to address untreatable brain diseases, with an initial focus on ALS.

School of Life Sciences and Technology, Indonesia Wins XVI Fujio Cup Quiz in NCRM NICHE 2021; Rajalakshmi Engineering College, India, Emerge Runners.

Retrieved on: 
Tuesday, October 19, 2021
University, Stem Cells, Biotechnology, Education, Other Health, Diabetes, Health, General Health, Research, Infectious Diseases, Science, Kyoto University, Virus, Endoplasmic reticulum stress in beta cells, School, List of life sciences, Centre for Regenerative Medicine, Technology, NASH, Regenerative medicine, Rajalakshmi Engineering College, Medical school, FCQ, B cell, Diabetes, Trust, Multimedia, Yokohama City University, GN, Research, NIMHANS, TN, Autism spectrum, University, Ensō, Global health, NHS trust, CSO, Longevity, National Centre for Science Information, Partnership, University of Toronto, NAFLD, GSZ, Cell Transplantation, Non-alcoholic fatty liver disease, NCRM, Solution, University of Cologne, Lists of diseases, EELS, COVID-19, XVI, Hiroshima University, Kasturba Medical College, Pharmaceutical industry

This press release features multimedia.

Key Points: